Sermorelin
Also known as: GRF 1-29, Geref
Sermorelin is a synthetic fragment of growth hormone releasing hormone (the first 29 amino acids). It was historically used as a diagnostic agent but is not currently approved for general human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported ~10-20 minutes (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Historically a registered diagnostic agent (testing pituitary function); not currently approved for general human use in Australia. Marketed therapeutic products have largely been discontinued.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to stimulate the pituitary to release growth hormone
- Historically used to assess pituitary growth hormone reserve
- Users report interest in sleep, recovery and body composition
- Early research indicates effects on IGF-1 levels
How it is reported to work
Sermorelin is reported to correspond to the active 1-29 fragment of growth hormone releasing hormone and to bind GHRH receptors on the pituitary, prompting a pulsatile release of the body's own growth hormone. Because it works through the natural feedback system, it is described as producing a more physiological pattern than direct growth hormone. These descriptions come largely from older clinical and diagnostic literature.
Background
Sermorelin is a growth hormone releasing hormone analogue consisting of the first 29 amino acids (GRF 1-29) - the portion considered biologically active. Historically it had a defined medical role as a diagnostic agent used to probe how well the pituitary could release growth hormone. This page is educational information, not medical advice.
What the research actually shows
Older clinical literature supports sermorelin’s reported ability to stimulate growth hormone release and its use in pituitary function testing. Contemporary claims about anti-ageing or body composition benefits are not well established and rest on limited modern evidence.
| Evidence type | Status |
|---|---|
| Older diagnostic literature | Present |
| Modern long-term trials | Lacking |
| Australian current approval | None |
What people use it for (reported)
Online, people report using sermorelin in attempts to support sleep, recovery and body composition. These are anecdotal reports, not validated clinical results. Studies suggest the mechanism involves the GHRH receptor, but reported benefits should not be read as established facts.
Things to be aware of
Sermorelin is not currently approved for general human use in Australia. Growth hormone pathway manipulation can have unintended effects, and grey-market product identity and purity cannot be verified by sight.
If you have a health or recovery concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using sermorelin.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to stimulate the pituitary to release the body's own growth hormone
- Reported to produce a more natural, physiological growth-hormone pattern than direct HGH
- Users report improved sleep quality
- Reported to support recovery and body composition over time
- Reported to raise IGF-1 levels gradually
Common side effects
- Injection-site reactions such as redness, swelling or pain
- Facial flushing or warmth after injection
- Headache
- Drowsiness, especially with evening dosing
- Hyperactivity or restlessness reported by some users
Rare / serious side effects
- Changes in blood-sugar handling
- Joint pain or fluid retention from sustained growth-hormone elevation
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Sermorelin. Listed so you can make an informed decision, not to suggest any use is safe.
- Chronic high-dose use is reported to risk down-regulating the body's own growth-hormone production, undermining the natural feedback it is meant to work with
- Overuse is reported to risk fluid retention, joint aches and carpal-tunnel-type symptoms consistent with growth-hormone excess
- Sustained IGF-1 elevation from overuse raises a commonly cited theoretical concern about feeding abnormal tissue growth
- Prolonged overstimulation of the pituitary is reported to risk blunting its natural responsiveness over time
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Sleep changes are often reported within days, while recovery and body-composition effects are reported to build gradually over several months.
First effects
Improved sleep within days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Fuller effects reported ~16-24 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Sermorelin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 200–500 mcg per dose |
| Frequency | Reported as once daily (often nightly before bed) |
| Cycle length | Reported cycles of about 8–12 weeks, then a break |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 200 mcg (0.2 mg) dose ≈ 0.08 mL = 8 units on a U-100 insulin syringe; a 500 mcg (0.5 mg) dose ≈ 0.2 mL = 20 units.
Work out the units for your vial → CalculatorCommonly reported community patterns describe a once-daily injection, often before bed to align with the natural overnight growth-hormone pulse, run over cycles of several months. These are reported patterns only, not a recommendation, and sermorelin is not currently approved for general human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported pairing of a GHRH analogue with a ghrelin-mimetic to amplify the growth-hormone pulse
Reported as a gentler ghrelin-mimetic partner for growth-hormone support
A related, longer-acting GHRH analogue that users compare or rotate with
Safety notes
Sermorelin is not currently approved for general human use in Australia, and modern long-term safety data is limited. Manipulating growth hormone pathways carries risks, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.